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Abstract
Assessment of a tumor’s molecular makeup using biofluid samples, known as liquid biopsy, is a 
prominent research topic in precision medicine for cancer, due to its noninvasive property allowing 
repeat sampling for monitoring molecular changes of tumors over time. Circulating exosomes 
recently have been recognized as promising tumor surrogates because they deliver enriched 
biomarkers, such as proteins, RNAs, and DNA. However, purification and characterization of these 
exosomes are technically challenging. Microfluidic lab-on-a-chip technology effectively addresses 
these challenges owing to its inherent advantages in integration and automation of multiple 
functional modules, enhancing sensing performance, and expediting analysis processes. In this 
article, we review the state-of-the-art development of microfluidic technologies for exosome 
isolation and molecular characterization with emphasis on their applications toward liquid biopsy–
based analysis of cancer. Finally, we share our perspectives on current challenges and future 
directions of microfluidic exosome analysis.
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Introduction
Tissue biopsy is often required for cancer diagnosis and prognosis. However, tissue biopsy is 
highly invasive for most primary tumors and metastatic diseases,1,2 especially brain cancer, 
lung cancer, and ovarian cancer, which require difficult surgeries.3 The obtained tissue 
quality and quantity highly determine the diagnostic precision at the molecular level, 
including mutation characterization. Tumor tissues are heterogeneous and evolve over 
time.2,4 Sampling of entire tissue with dynamic representatives is not possible. Therefore, 
assessment of the molecular makeup of tumors from a biofluid sample is of great research 
interest.2 Although technology challenging, noninvasive blood-based liquid biopsy allows 
repeat monitoring for clinical oncologists to gain a broader molecular understanding of 
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tumors without the need for a tissue biopsy.5,6 Indeed, several blood-based biomarker tests 
that have been developed have been around for decades and are still debatable, including 
prostate-specific antigen (PSA) screening for prostate cancer, carcinoembryonic antigen 
(CEA) for colorectal cancer, CA19-9 for pancreatic cancer, and CA125 for ovarian cancer, 
due to the lack of reliability and specificity.7,8 Recent technological developments being 
applied to liquid biopsies are capable of reproducibly detecting mutations at very low allelic 
frequencies.9 However, lack of confidence in blood-based biomarkers still prevents 
widespread utilization of liquid biopsy for cancers.
Recent research of extracellular vesicles (EVs) and exosomes has revealed that early-stage 
tumors constitutively release vesicles carrying various tumor markers.10–12 Exosomes, 
which are membrane vesicles of endocytic origin (30–150 nm diameter, Fig. 1), are 
systemically detectable in the blood of various cancer patients and have been shown to 
correlate well with tumor progression, immune response suppression, angiogenesis, and 
metastasis.13–15 Exosomes are stable carriers of enriched genetic material and proteins from 
their cell of origin, thereby holding great promise for identifying early-stage tumors.16,17 
Compared to well-studied circulating tumor cells (1–10 circulating tumor cells [CTCs]/mL 
of blood), exosome release from tumor cells is an active process with concentrations of ≥109 
vesicles/mL in blood.11,18 As illustrated in Figure 2, exosomes sensitively reflect tumor 
status; therefore, substantial investigations have focused on the essential physiologic and 
pathophysiologic functions of circulating exosomes as a surrogate for tumor liquid 
biopsy.14,19–22
However, isolation and molecular analysis of such diverse nanoscale exosome vesicles for 
clinical utilization are technically challenging.21,23–26 Size overlap complicates exosome 
definition due to the presence of other membrane-derived subcellular structures, such as 
apoptotic vesicles, exosome-like vesicles, membrane particles, and ectosomes.27,28 Current 
exosome purification methods, including ultrafiltration and sucrose gradient 
ultracentrifugation, are tedious and time-consuming (>10 h) and cannot completely 
discriminate exosomes from other EVs.29–31 Although conventional filtration isolates 
microvesicles (MVs) with a uniform size of less than 150 nm, forced filtration and shearing 
force may cause membrane fusion and loss of integrity.32 Molecular analysis of isolated 
MVs is primarily performed using Western blot, enzyme-linked immunosorbent assay 
(ELISA), or mass spectrometry, which require lengthy processes and concentrated exosome 
samples.33 Nanoparticle tracking analysis (NTA) and flow cytometry have demonstrated 
limited reliability for detecting particles smaller than 200 nm.33,34 Transmission electron 
microscopy (TEM) and atomic force microscopy (AFM) have been utilized often to 
investigate exosome morphology and size distribution (Fig. 2),35 but microscopic protocols 
do not inherently exhibit high-throughput and rapid measurement. Microfluidic lab-on-a-
chip technology has recently been spotlighted as a promising approach for exosome 
isolation and molecular analysis, owing to its low-volume consumption,36 high capability of 
functional module integration,37 quick analysis time, and high sensitivity,38 as well as a 
sample-to-answer format.39–41 Several microfluidic approaches, such as isolation, 
quantification, and molecular profiling, have been previously developed for exosome 
study.42 We review the state-of-the-art microfluidic technologies for isolating exosomes and 
their applications for exosome-based liquid biopsy analysis of cancer. Other emerging 
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microfluidic approaches developed for fabrication and production of therapeutic exosomes43 
are not within the scope of this article.
Microfluidic Exosome Isolation
Since 2012, research efforts have increased dramatically to develop microfluidic platforms 
in order to isolate exosomes. Compared to benchtop methods, microfluidic technology offers 
fast isolation speed, high yield and efficiency, automation, and functional integration for 
streamlined exosome molecular analysis.42 Vesicle size (30–150 nm) and surface markers 
(immunoaffinity) are mandatory in order to identify a specific population of circulating MVs 
that primarily consists of exosomes.10 Therefore, current reported microfluidic platforms 
can be classified as immunoaffinity-based exosome isolation and size-based exosome 
isolation.
Immunoaffinity-based exosome isolation can be implemented into microfluidic devices by 
manipulating affinity particles/magnetic beads, or modifying microchannel surfaces with 
antibodies. In 2010, Chen et al. reported the first microfluidic exosome isolation platform, 
which used an anti-CD63 functionalized surface for immunocapture of exosomes from 
human sera.44 Kanwar et al. developed a similar platform called ExoChip, which utilized a 
surface-functionalized (anti-CD63) circular microchamber to capture exosomes, followed by 
fluorescent carbocyanine dye (DiO) staining for quantitation.45 Although various 
microstructures were configured to enhance mixing and capture efficiency, capture capacity 
was still limited by available surface area and antibody immobilization density. Therefore, 
spherical particles or immunomagnetic beads were introduced into microfluidic devices to 
enhance capture capacity. We recently reported two microfluidic platforms46,47 for large-
scale exosome isolation and molecular profiling of both surface and intravesicular markers 
by manipulating immunomagnetic capture beads in a microfluidic, multistage circuit. 
Dudani et al. introduced 20 μm polystyrene beads conjugated with biotinylated anti-human 
CD63 into a microfluidic device that utilized inertial lift forces at a finite Reynolds number, 
in order to position microparticles and exchange solutions for rapid purification.48 This 
approach provided high-flow-rate isolation of exosomes, which greatly increased throughput 
and processing volume compared to other methods. However, premixing and incubation of 
capture beads with samples were needed.
Although immunoaffinity-based isolation generates specific exosome populations and 
reflects molecular expression levels, size-based isolation has advantages of size uniformity 
without sample bias. Wang et al. fabricated a microfluidic device consisting of an array of 
porous silicon nanowire-on-micropillar.49 The inter-nanowire spacing was tuned within a 
range of 30–200 nm to create a high density of interstitial sites, which allowed physical trap 
of exosomes. Davies et al. in situ prepared nanoporous membranes in a microfluidic 
filtration system to isolate vesicles from whole blood with tunable size cutoff (<500 nm).50 
However, these physical trapping approaches were restricted by exosome saturation limit 
and recovery rate. A continuous flow design, without capacity limitation, is ideal for on-chip 
high-throughput processing and integration of downstream sample preparation. Lee et al. 
developed an acoustic nano-filter chip that can fractionate exosomes (diameter < 200 nm) 
from cell culture media and blood in a continuous flow manner.51 Santana et al. built a 
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microfluidic obstacle array based on the principle of deterministic lateral displacement and 
fractionated MVs with size cutoff of 250 nm.52 Currently, isolation with greater size 
resolution below 200 nm still needs to be improved.
Table 1 summarizes exosome isolation performance from various microfluidic platforms in 
terms of yield, capacity, and efficiency. As shown in the table, microfluidic technology as an 
advanced approach substantially increased exosome isolation speed and efficiency compared 
to a classic benchtop ultracentrifugation approach. In addition, it has been reported that 
diverse subpopulations of vesicles secreted by various intracellular mechanisms were present 
in exosome preparations obtained by differential ultracentrifugation.31 Although size is the 
most acceptable criterion for exosome identification (smaller than 150 nm), it is not a strict 
feature of exosomes. Several current preparations invariably contain varying proportions of 
other membranous vesicles that co-purified with exosomes, such as shed MVs and apoptotic 
blebs. Tauro et al. observed that EpCAM immunoaffinity-captured exosomes contain at least 
double the amount of enriched exosome markers and exosome-associated proteins, 
compared to centrifugation and density-based separations, although these MVs all range 
from 40 to 100 nm.53 Therefore, it is crucial in the future to design novel microfluidic 
methods that combine size and marker features for purifying and characterizing vesicle types 
and allowing precise analysis of respective exosome functions.
Microfluidic Exosome Sensing toward Liquid Biopsy
Liquid biopsy analysis of tumors has beneficially impacted clinical care, especially 
regarding treatment decision guidance; exosomes are significant contributors to such 
progress.54 Several advanced microfluidic exosome measurement and sensing technologies 
have been developed to characterize exosome physical, biological, and molecular properties. 
Akagi et al. developed a microfluidic immunoelectrophoresis approach to detect bound 
antibodies to exosome surface markers without need of fluorescent labeling.55 
Immunobinding of exosomes with antibodies has resulted in zeta potential changes, thus 
exhibiting different migration mobilities under electrophoresis depending on marker 
expression levels. Equipped with a laser dark-field microscope, this platform can measure 
size, zeta potential, and surface markers from exosomes.55 In contrast to flow cytometry, this 
method does not require fluorescent labeling for detecting bound antibodies. Additionally, 
the shift in the zeta potential is not associated with the size of vesicles, as long as the density 
of bound antibodies is not changed. However, the sensitivity or resolution of the zeta 
potential change in terms of exosome particle number has not been discussed, and the 
equipment setup is relatively expensive and complicate. Vaidyanathan et al. introduced a 
tunable alternating current electrohydrodynamic flow (nanoshearing) in a microfluidic 
channel that enhances the specificity of capture for sensitive detection of exosomes.56 The 
multiplexed device allows simultaneous detection of multiple exosome markers on-chip 
using colorimetric readout visible to the naked eye. The detection method is simple and 
straightforward. Quantitative detection of markers HER2, PSA, and CD9 was demonstrated 
for breast cancer diagnosis. More efforts have been made to extract intravesicular exosomal 
biomarkers (microRNA) for seeking interconnections with cancer disease study and 
diagnostic potential. Taller et al. substantially improved exosome lysing and the RNA 
detection process in ~1.5 h by integrating a surface acoustic wave with an ion exchange 
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nanomembrane sensor.57 Note that conventional benchtop methods require at least ~24 h of 
processing time. Wei et al. employed a nonuniform electrical field to disrupt exosomes and 
release harbored exosomal RNA/protein biomarkers for on-site monitoring through immune 
recognition.58,59 The hCD63-GFP expressing exosomes from lung cancer cell line H460, 
which was stably transfected with hCD63-GFP, were found in vivo to transport to saliva, in 
addition to serum.
In order to profile both surface and intravesicular exosomal markers, we have developed a 
cascading chip to integrate exosome isolation, enrichment, chemical lysis, protein 
immunoprecipitation, and sandwich immunoassay assisted by chemifluorescence detection47 
(Fig. 3a,b). Analysis of both type 1 insulin growth factor receptor (IGF-1R) and its 
intravesicular phosphorylation status from non-small-cell lung cancer patient plasma-derived 
exosomes was demonstrated. Significant overexpression of exosomal IGF-1R was observed 
in lung cancer patients compared to healthy individuals. In addition, we employed an 
ExoSearch chip for blood-based diagnosis of ovarian cancer using multiplexed measurement 
of three exosomal tumor markers (CA125, EpCAM, CD24) from the same population of 
CD9 positive exosomes46 (Fig. 3c). Results showed significant diagnostic power (a.u.c. = 
1.0, p = 0.001) through a training set of ovarian cancer patient plasma (Fig. 3d,e). In 
contrast, the diagnostic accuracy of using exosomal particle concentrations measured by 
NTA was poor, with an a.u.c. of only 0.67 (Fig. 3f), due to the relative large uncertainty in 
size and concentration measured by NTA. Note that counting exosomes alone has been 
found insufficient for cancer diagnosis. The results from receiver operating characteristic 
(ROC) analysis suggested that ExoSearch chip enables sensitive multiplexed exosomal 
marker detection for blood-based diagnosis of ovarian cancer with significant predictive 
power. In order to further improve the exosome detection sensitivity and boost the limit for 
early detection of cancer, we recently introduced a novel graphene oxide/polydopamine 
(GO/PDA) nanointerface.60 The GO-induced formation of 3D nanoporous PDA surface 
coating enabled ultrasensitive on-chip ELISA assay of ovarian cancer plasma-derived 
exosomes at 50 exosomes/μL.
Dr. Hakho Lee’s research group pioneered a study of diagnostic and prognostic roles of 
circulating exosomes using microfluidic sensing technology. In 2012, Shao et al. devised a 
microfluidic nuclear magnetic resonance system (μNMR) in which MVs bound with marker-
specific magnetic nanoparticles resulted in faster decay of the NMR signal depending on 
protein expression levels (Fig. 4a). The significance of using blood exosomes in diagnosis 
and monitoring treatment responses for patients with glioblastoma was demonstrated by 
probing nine exosomal markers.61 Efficacy of drug treatment, including temozolomide 
(TMZ) and geldanamycin, has been evaluated using μNMR, as MV numbers decreased in 
proportion to drug concentration. This platform has better detection sensitivity than standard 
ELISA and flow cytometry analyses, and further enhancement of sensitivity is under 
development. Rho et al. refined the exosome sample preparation step in integration with 
μNMR. A filter membrane cartridge was incorporated to directly isolate and enrich 
exosomes from blood before labeling with target-specific magnetic nanoparticles for μNMR 
sensing.62 Im et al. introduced a nanoplasmonic exosome (nPLEX) assay platform that 
consists of arrays of lattice nanoholes patterned in a gold film within parallel microfluidic 
channels for label-free, surface plasmon resonance (SPR) sensing (Fig. 4b).63 Ascites 
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samples from ovarian cancer patients and 10 ovarian cancer cell lines were studied by 
probing 71 exosomal protein markers. Levels of EpCAM and CD24 markers showed 
significant responses for improving ovarian cancer diagnosis with an accuracy of 97%. The 
nPLEX platform provided high-throughput screening capability with improved sensitivity, 
compared to μNMR platform. However, the system complexity of both nPLEX and μNMR 
requires nanofabrication and skilled operations, which limits the application in routine 
clinical tests. In 2015, Shao et al. expanded the work by investigating exosomal mRNA in 
glioblastoma patient blood during treatment, since serial rebiopsy of primary tumors is 
difficult.64 Real-time PCR analysis of RNA contents released from immunomagnetically 
captured exosomes was integrated into a microfluidic chip (iMER) for studying key 
exosomal mRNA markers that could probe epigenetic status of a primary tumor and 
potentially predict TMZ drug resistance. Results from the above several novel platforms 
supported the use of exosomes as tumor cellular surrogates. In parallel with CTC research, 
exosomes were shown to be abundant and stable in circulation, providing significant 
practical value as surrogates of tumors for liquid biopsy (Fig. 2).
Discussion
Tumor-derived circulating exosomes have attracted increasing interest for noninvasive 
cancer diagnosis and monitoring of treatment response, as a promising alternative to liquid 
biopsy. In addition to microfluidic technology, several other emerging approaches have been 
implemented to study exosomes and their molecular compositions, such as single exosome 
detection,65,66 SPR and imaging,67–70 magnetoelectrochemical sensor,71 ExoScreen 96-well 
plate,72 and EV array.73,74 We summarized detection sensitivity and sensing capability in 
Table 2, which showed superior performance compared to conventional Western blotting 
analysis and chemiluminescence ELISA. Such improvements in terms of analytical 
sensitivity and specificity will greatly address current hurdles in liquid biopsy of cancers. 
We foresee that a growing number of investigators across disciplines will devote more 
efforts to advancing exosome research in the next 5 years and beyond.
Exosome secretion is a dynamic process, producing diverse populations with 5-fold 
differences in size and 104-fold differences in concentration;27 as a result, precise 
measurement and analysis of exosomes is challenging. To date, standardized isolation 
protocols are still lacking, and the field of exosome research lags behind CTC research 
because the definition and characterization of exosome types are not yet firmly established. 
Specific exosomal markers for quantitative evaluation of exosomes with cell origins are 
urgently needed. In order to increase understanding of exosomes and quantitatively decipher 
exosomal components, more novel technologies are needed for comprehensive 
characterization of surface and intravesicular compositions. Interconnections between 
exosomal RNA, surface protein topography, and posttranslational modification could aid 
identification of exosome associated with cancer phenotypes. It is worth mentioning that 
increased MV counts with prolonged storage of blood have been observed, but the protein 
profile per vesicle in blood displayed negligible changes during blood aging based on Rho et 
al.’s study.62 These findings point out that sample preparation protocols are critical and need 
to be standardized. Using highly precise fluid control and automation, microfluidic 
technology has the capability to address the above issues in sample preparation and 
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isolation, with more power for molecular characterization and sensitive detection. However, 
in order to achieve clinical utilities in liquid biopsy for cancer, tremendous efforts are still 
needed to improve the adaptability of the microfluidic technologies to clinical settings and 
promote the commercialization of the systems. Some of the microfluidic platforms described 
above require off-chip sample preparation steps, which introduce extensive manual 
interventions. Microfluidic technologies are still largely developed for operation under the 
research settings and require expensive setup and well-trained professional to run tests. 
Simple colorimetric or mobile device–based readout from blood drops is garnering great 
interest. Other essential research efforts include improving exosome processing throughput 
and enhancing assay reliability. Overall, in addition to providing new abilities to better 
elucidate the biology and clinical relevance of exosomes, robustness and ease of use will be 
the key considerations in microfluidic research to drive the benchtop-to-bedside transition of 
both technology innovation and scientific advances in exosome biology. Cancer is a 
complicated and dynamic disease. For accomplishing personalized cancer medicine, the 
development of a reliable, novel liquid biopsy platform will have tremendous benefit. We 
anticipate that microfluidic technology will play a game-changing role in exosome analysis 
and liquid biopsy of cancer.
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Exosome biogenesis, properties, and molecular composition.
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Circulating tumor antigens, exosomes, and CTCs associated with tumor status (not to scale). 
Scale bar shows the detection resolution of various benchtop instruments.
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Microfluidic analysis of exosomal protein markers for liquid biopsy of cancer. (a) 
Polydimethylsiloxane chip containing a microchannel network for cascading exosome 
analysis. (b) Integration of streamlined on-chip immunomagnetic isolation of exosomes, 
chemical lysis, and intravesicular protein analysis. (c) Setup of ExoSearch chip for 
continuous mixing, isolation, enrichment, and multimarker probing of circulating exosomes. 
(d) Expression level and ROC analysis (e,f) of three tumor markers (CA125, p < 10−4; 
EpCAM, p = 0.0009; CD24, p = 0.003) from blood plasma–derived exosomes (nOvCa = 15, 
nhealthy = 5) using ExoSearch chip, compared to standard Bradford assay and NTA analysis 
of ultracentrifugation-purified exosomes from matched human subjects. Ovarian cancer 
patients are represented by red dots, and healthy controls are represented by blue dots. 
(Figures are adapted with permission from the Royal Society of Chemistry.)
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Microfluidic exosome molecular profiling for monitoring of disease and treatment. (a) 
μNMR chip with two-step labeling of target proteins on MVs using magnetic nanoparticles. 
The μNMR microfluidic system is designed to monitor TMZ drug treatment responses for 
patients with glioblastoma, as MV numbers decrease in proportion to drug concentration. (b) 
The nPLEX chip evaluated ascites-derived exosomes from ovarian cancer and noncancer 
patients. Cancer exosomes were captured on EpCAM and CD24-specific sensor sites, which 
led to intensity changes in the transmitted light (left scheme of principle). The nPLEX chip 
was integrated with a multichannel microfluidic cell for independent and parallel analyses. 
Transmission intensities of 12 × 3 nanohole arrays can be measured simultaneously using 
the imaging setup. (c) The microfluidic iMER chip was developed to integrate (1) capture of 
cancer exosomes in serum with magnetic microbeads containing affinity ligands, (2) 
immunoenrichment of exosomal population and lysing for flowing through a glass bead 
filter and RNA extraction, and (3) elution and reverse transcription for real-time 
amplification and quantitation. SEM image scale bars are 500 nm, 100 nm (inset). The 
device has been used for analyzing mRNA levels of drug resistance markers DNA 
ethyltransferase (MGMT) and alkylpurine-DNA-N-glycosylase (APNG) in enriched tumor 
exosomes obtained from blood. (Figures are adapted with permission from Nature 
Publishing Group.)
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Table 2
Detection Performance of Exosome Sensing Technologies.
Approaches Detection Sensitivity Detection Multiplexity Markers Detected Reference
ExoChip 0.5 pM Doi dye staining, no multiplexity CD63 capture exosomes 
and extract total RNA
45
ExoSearch chip 750 particles/μL Simultaneous detection of 3 
markers
CA125, EpCAM, and 
CD24
46
nPLEX chip 1000 particles/μL Parallel detection of 12 potential 
exosomal markers
EpCAM, CD24, CA125, 
CA19-9, HER2, MUC18, 
EGFR, CLDN3, CD45, 
CD41, D2-40
59
GO/PDA nano-IMEX 50 particles/μL (80 aM) Single-plex sandwich ELISA D9, CD63, CD81, 
EpCAM
60
iMEX chip 104 particles/μL 8 channels for simultaneous 
detection of 4 markers
EpCAM, CD24, CA125, 
CD63, HER2, MUC18, 
EGFR
67
μNMR chip 2 × 106 particles/μL Magnetic nanoparticle labeling EGFR, PDGFR-α, 
PDPN, EphA2, 
EGFRvIII6, IDH1 
R132H, HSP90, CD41, 
MHCII
57
ExoScreen plate ELISA grade 96-well plate CD9, CD63, CD147, 
CEA, CA19-9
68
Nanoshearing microfluidic approach 2760 particles/μL Simultaneous detection of 3 
markers
HER2, PSA, CD9 56
EV array 5000 particles/μL Simultaneous detection of 21 
markers
CD9, CD63, CD81, TNF 
RI, TNF RII, HSAP90, 
HLA-ABC, GRP78, 
Mucin16, PLAP, SPA, 





SPR approach 4.87 × 104 particles/μL, 
or low picomolar
No multiplexity CD63, CD9, CD24, 
CD44, EpCAM, HER2
63–66
FLOWER/laser dark-field imaging Single exosome No multiplexity N/A 61, 62
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